| |
Antobodies
That Detect a Novel Tumor Supressor (BIN1)
Implicated in Human Carcinomas and Apoptosis
Inventors:
George Prendergast, Daitoku Sakamuro
Tech
ID: PG01RR
Description:
Wistar researchers have developed polyclonal
and monoclonal antibodies (PAb 99Pst and
MAbs 99D through 99I) that bind to BIN1,
a novel tumor suppressor protein that
interacts with and inhibits the oncogenic
activity of the MYC oncoprotein. BIN1
is functionally deleted in carcinomas
of the breast, colon, lung, liver and
cervix and has been implicated in programmed
cell death (apoptosis). Apoptosis is an
active process of physiological cell suicide
that is critical to normal tissue homeostasis
but that does not function properly in
tumor cells. Work aimed at defining the
genetic control of apoptosis and understanding
its dysfunction in cancer has centered
on the MYC oncoprotein, because it can
promote either cell proliferation or apoptosis.
Wistar scientists theorize that BIN1 may
activate or facilitate apoptosis, thereby
overcoming MYC's malignant growth activity.
The antibodies generated by Wistar scientists
are useful for research aimed at understanding
the role of the BIN1 protein in the genetic
events associated with apoptosis.
Origin:
Anti-99Pst is derived from rabbits immunized
with a recombinant BIN1 polypeptide fused
to glutathione s-transferase. 99D-I are
secreted by hybridomas derived from mice
immunized with recombinant BIN1 polypeptide
fused to glutathione s-transferase. Isotypes
are IgG1
(E, G, H) and IgG2b(D,
E).
Reactivity:
The polyclonal antibody recognizes BIN1
and at least one additional BIN1-related
protein. This antibody does not appear
to recognize the murine BIN1 polypeptide
and therefore appears to be human-specific.
The monoclonal antibodies are specific
for BIN1 but recognize proteins from human,
murine, rat, and avian cells. The epitope
recognized by 99F, 99G, 99H, and 99I has
been mapped to a 10-residue region of
BIN1. Two other epitopes mapping outside
of this region are recognized by the three
other antibodies.
Intellectual
Property Status: United States
patent has been allowed.
Contact:
Meryle J. Melnicoff, Ph.D.
Director, Business Development The Wistar Institute
Phone: (215) 898-0049
melnicoff@wistar.org
|
|
